TT 701Alternative Names: LY 2452473
Latest Information Update: 14 Sep 2016
At a glance
- Originator Eli Lilly
- Developer Brigham and Women's Hospital; Dana-Farber Cancer Institute; Eli Lilly; Transition Therapeutics
- Class Erectile dysfunction therapies
- Mechanism of Action Androgen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Erectile dysfunction; Prostate cancer